Skip to main content

McKesson Corporation (MCK) Stock Analysis

SellModerate Confidence

Healthcare · Medical Distribution

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $809.69: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.33; Below-average business quality; Negative price momentum.

McKesson is a diversified healthcare services company distributing branded, generic, specialty, and OTC pharmaceuticals through 27 US distribution centers to pharmacies, hospitals, and oncology practices, alongside RxTS prescription technology services, medical-surgical... Read more

$809.69+10.2% A.UpsideScore 5.8/10#1 of 5 Medical Distribution
Stop $775.68Target $891.78(analyst − 10%)A.R:R 2.0:1
Analyst target$990.87+22.4%15 analysts
$891.78our TP
$809.69price
$990.87mean
$1107

Sell if holding. Engine safety override at $809.69: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.33; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.8/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: moderate.

Val6.1Qual3.6Grw7.5Mom3.3Sent7.9Ins5.0Peer4.9Tech8.1Risk7.25.8OVERALL

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.6 < 4.0)

Key Metrics

P/E (TTM)23.8
P/E (Fwd)18.7
Mkt Cap$100.8B
EV/EBITDA18.2
Profit Mgn1.1%
ROE—
Rev Growth11.4%
Beta0.42
Dividend0.40%
Rating analysts22

Quality Signals

Piotroski F6/9

Options Flow

P/C1.33bearish
IV50%normal
Max Pain$1300+60.6% vs spot

Material Events(8-K, last 90d)

  • 2026-03-05Item 5.02MEDIUM
    CFO Britt J. Vitalone notified intention to retire, last day as CFO May 28, 2026. Kenny K. Cheung appointed EVP and CFO effective May 29, 2026; previously CFO at Sysco Corporation.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
1.1
Ma Position
2.2
Rsi
3.0
Obv
10.0
Capitulation risk (RSI 20, below 200MA)Volume accumulation (rising OBV)Below 200-MA but MA still rising (+2.7%/30d) — pullback in uptrend, not confirmed weakness

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin
0.0
Net Margin
0.5
Operating Margin
0.6
Roa
2.9
Current Ratio
3.5
Moat
5.0
Piotroski F
6.7
Fcf Quality
10.0
Excellent cash conversion: 211% FCF/NINo competitive moat
GatesMomentum 3.3<4.5EARNINGS PROXIMITY 7d<=7dA.R:R 2.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Moderate
RSI
20 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $791.09Resistance $887.25

Price Targets

$776
$892
A.Upside+10.1%
A.R:R2.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.6 < 4.0)
! Momentum score 3.3/10 — below 4.5 minimum
! EARNINGS_PROXIMITY:7d<=7d

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is MCK stock a buy right now?

Sell if holding. Engine safety override at $809.69: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.33; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $775.68. Score 5.8/10, moderate confidence.

What is the MCK stock price target?

Take-profit target: $891.78 (+10.2% upside). Prior stop was $775.68. Stop-loss: $775.68.

What are the risks of investing in MCK?

Quality below floor (3.6 < 4.0).

Is MCK overvalued or undervalued?

McKesson Corporation trades at a P/E of 23.8 (forward 18.7). TrendMatrix value score: 6.1/10. Verdict: Sell.

What do analysts say about MCK?

22 analysts cover MCK with a consensus score of 4.2/5. Average price target: $991.

What does McKesson Corporation do?McKesson is a diversified healthcare services company distributing branded, generic, specialty, and OTC pharmaceuticals...

McKesson is a diversified healthcare services company distributing branded, generic, specialty, and OTC pharmaceuticals through 27 US distribution centers to pharmacies, hospitals, and oncology practices, alongside RxTS prescription technology services, medical-surgical distribution, and international pharmacy operations in Canada and Norway.

Related stocks: CAH (Cardinal Health, Inc.) · COR (Cencora, Inc.) · INCY (Incyte Corporation) · NBIX (Neurocrine Biosciences, Inc.) · LLY (Eli Lilly and Company)